# EDGAR Filing Document

**Accession Number:** 0001971532
**File Stem:** 0001493152-26-005199
**Filing Date:** 2026-2
**Character Count:** 6735
**Document Hash:** 00f0331448f78a76f1e584e40c486590
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-005199.hdr.sgml**: 20260205

**ACCESSION NUMBER**: 0001493152-26-005199

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260205

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260205

**DATE AS OF CHANGE**: 20260205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Telomir Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001971532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 872606031
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41952
- **FILM NUMBER:** 26600444

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SE 2ND ST
- **STREET 2:** SUITE 2000 #1009
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131
- **BUSINESS PHONE:** 786-396-6723

**MAIL ADDRESS:**
- **STREET 1:** 100 SE 2ND ST
- **STREET 2:** SUITE 2000 #1009
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 5, 2026**

**TELOMIR PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Florida** | **001-41952** | **87-2606031** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**100 SE 2nd St, Suite 2000, #1009**

**Miami, Florida 33131**

**(Address of Principal Executive Offices)**

**Registrant's telephone number, including area code: (786) 396-6723**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> <u>Trading Symbol</u> <u>Name of each exchange on which registered</u> <br> Common Stock, no par value TELO The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 – Other Events**

**Telomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging**

*Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity—without relying on cytotoxic mechanisms.*

On February 5, 2026, Telomir Pharmaceuticals, Inc. (the "Company") reported new findings from preclinical cellular studies evaluating its lead investigational compound, Telomir-1, in the form of Telomir-Zn.

In these studies, done in collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to induce a rapid and coordinated intracellular redistribution of metals, characterized by **increased intracellular zinc levels and a reciprocal reduction in labile ferrous iron**. The effects were dose-dependent, detected within approximately 30 minutes of exposure, sustained over a two-hour period, and observed **without loss of cell confluence or viability** in the evaluated cellular models. Zinc accumulation and iron reduction occurred over similar concentration ranges and timeframes, supporting a coordinated intracellular process rather than independent or nonspecific metal effects.

Iron and zinc play fundamentally different roles in cellular biology. **Excess labile iron is redox-active and can drive reactive oxygen species generation**, contributing to mitochondrial damage, DNA instability, and dysregulation of metal-dependent epigenetic enzymes. **Zinc, by contrast, is redox-inert and supports chromatin structure, DNA repair, antioxidant defenses, and proper regulation of epigenetic processes**. The observed simultaneous reduction of redox-active iron and enrichment of intracellular zinc suggests a metal-exchange process that may reduce oxidative stress while stabilizing epigenetic and mitochondrial function.

**These findings are significant because dysregulated metal balance, oxidative stress, and epigenetic instability are shared upstream drivers of both cancer biology and age-related cellular decline.** By demonstrating coordinated zinc–iron modulation, the reported data support a mechanism that acts at a foundational biological level rather than targeting downstream disease manifestations.

The Company also reported that it continues to advance a portfolio of ongoing and completed preclinical research programs, including studies in **triple-negative breast cancer models** and **longevity-focused models**. Based on data generated from completed studies, **manuscript submissions to peer-reviewed journals have been initiated**, while additional data continue to be generated from ongoing preclinical studies.

In addition, the Company reported that it is finalizing IND-enabling activities and currently plans to submit an Investigational New Drug application in the first quarter of 2026.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TELOMIR PHARMACEUTICALS, INC.** | **TELOMIR PHARMACEUTICALS, INC.** |
| Dated: February 5, 2026 | By: | */s/ Erez Aminov&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* |
|  | Name: | Erez Aminov |
|  | Title: | Chief Executive Officer |

---